Eiger BioPharmaceuticals, Inc. Stock price

Equities

EIGR

US28249U2042

Biotechnology & Medical Research

Delayed Nasdaq 01:54:26 2024-03-28 pm EDT 5-day change 1st Jan Change
5.005 USD +0.50% Intraday chart for Eiger BioPharmaceuticals, Inc. -16.02% -25.69%
Sales 2023 * 18.45M Sales 2024 * 25.22M Capitalization 7.37M
Net income 2023 * -72M Net income 2024 * -24M EV / Sales 2023 * 0.4 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.29 x
P/E ratio 2023 *
-0.1 x
P/E ratio 2024 *
-0.32 x
Employees 56
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.2%
More Fundamentals * Assessed data
Dynamic Chart
Eiger BioPharmaceuticals, Inc. Announces Christine A. Murray Notifies Resignation as Member of Board of Directors, Effective March 15, 2024 CI
Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024 CI
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Biotechnology Index CI
Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs DJ
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (EIGR) EIGER BIOPHARMACEUTICALS Posts Q3 Revenue $3.2M MT
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P Global BMI Index CI
Eiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing Talks DJ
Eiger to discontinue hepatitis drug study over safety concerns RE
Eiger to discontinue hepatitis drug study RE
Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta CI
Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating MT
More news

Latest transcript on Eiger BioPharmaceuticals, Inc.

1 day+0.50%
1 week-16.02%
Current month-10.62%
1 month-13.57%
3 months-37.33%
6 months-44.76%
Current year-25.69%
More quotes
1 week
4.79
Extreme 4.79
6.15
1 month
4.79
Extreme 4.79
8.27
Current year
4.79
Extreme 4.79
8.27
1 year
4.79
Extreme 4.79
43.35
3 years
4.79
Extreme 4.79
300.64
5 years
4.79
Extreme 4.79
474.60
10 years
4.79
Extreme 4.79
693.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 17-06-13
Director of Finance/CFO 58 23-04-12
Compliance Officer 55 23-04-12
Members of the board TitleAgeSince
Director/Board Member 57 22-07-17
Chairman 60 16-03-21
Chief Executive Officer 59 17-06-13
More insiders
Date Price Change Volume
24-03-28 5.005 +0.50% 3 229
24-03-27 4.98 -7.18% 4,748
24-03-26 5.365 -4.03% 20,165
24-03-25 5.59 -2.95% 7,549
24-03-22 5.76 -3.36% 13,310

Delayed Quote Nasdaq, March 28, 2024 at 01:54 pm EDT

More quotes
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.98 USD
Average target price
30 USD
Spread / Average Target
+502.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Eiger BioPharmaceuticals, Inc. - Nasdaq